WallStSmart

Cross Country Healthcare Inc (CCRN)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 7111% more annual revenue ($72.25B vs $1.00B). LLY leads profitability with a 35.0% profit margin vs -9.8%. LLY appears more attractively valued with a PEG of 1.58. LLY earns a higher WallStSmart Score of 76/100 (B+).

CCRN

Hold

36

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.25

LLY

Strong Buy

76

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 4.3Quality: 6.0
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCRNUndervalued (+37.2%)

Margin of Safety

+37.2%

Fair Value

$13.17

Current Price

$13.25

$0.08 discount

UndervaluedFair: $13.17Overvalued

Intrinsic value data unavailable for LLY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCRN3 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.2510/10

Safe zone — low bankruptcy risk

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$1.02T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

Areas to Watch

CCRN4 concerns · Avg: 2.3/10
Market CapQuality
$428.06M3/10

Smaller company, higher risk/reward

PEG RatioValuation
12.622/10

Expensive relative to growth rate

Return on EquityProfitability
-31.5%2/10

ROE of -31.5% — below average capital efficiency

Revenue GrowthGrowth
-17.8%2/10

Revenue declined 17.8%

LLY4 concerns · Avg: 2.8/10
PEG RatioValuation
1.584/10

Expensive relative to growth rate

Debt/EquityHealth
1.393/10

Elevated debt levels

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Price/BookValuation
33.5x2/10

Trading at 33.5x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : CCRN

The strongest argument for CCRN centers on Price/Book, Debt/Equity, Altman Z-Score.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bear Case : CCRN

The primary concerns for CCRN are Market Cap, PEG Ratio, Return on Equity.

Bear Case : LLY

The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

CCRN profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.

LLY carries more volatility with a beta of 0.51 — expect wider price swings.

LLY is growing revenue faster at 55.5% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (76/100 vs 36/100), backed by strong 35.0% margins and 55.5% revenue growth. CCRN offers better value entry with a 37.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cross Country Healthcare Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cross Country Healthcare, Inc. provides talent management and other consulting services for healthcare clients in the United States. The company is headquartered in Boca Raton, Florida.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?